Presentation Scheduled on Friday, June 10th, 2016 at 10:30 AM Eastern Time...

Presentation Scheduled on Tuesday, June 14th, 2016 at 2:50 PM Central Time...

Intellectual Property Portfolio Broadened for Its Proprietary Transdermal Delivery System...

Presentation Scheduled on Wednesday, July 13th, 2016 at 1:00 PM ET ...

Appoints Former Senior J&J Executive responsible for leading launch of ORTHO EVRA®...

Preparations Underway for Phase 2 Clinical Trial of Novel Twirla® Line Extension...

Industry Veteran Brings Significant Management and Commercial Experience...

Twirla® Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017; Cash Expected to Fund Operations Through the End of 2017...

Top-Line Data Expected in Early January 2017; Resubmission Planned for First Half 2017  Cash Expected to Fund Operations Through the End of 2017 PRINCETON, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company, today...

PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company announced today that it has received net proceeds of approximately $3 million in non-dilutive financing through the State of New Jersey's Technology Business...